RxDoctor Payments Data

Christopher Kannady

Urology · Houston, TXNPI 1780001966

Payments from drug & device makers

$12,590in general payments, 2019–2025

Across 212 payments — averaging $59.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$3K
  • Coloplast$3K
  • Boston Scientific$1K
  • Teleflex LLC$888
  • Procept Biorobotics Corporation$654
  • Astellas Pharma US Inc$552
  • plus $3K from 40 others

What the payments were for

  • Consulting fees$2,34419%
  • Travel & lodging$1,92615%
  • Food & beverage$8,00664%
  • Education$3152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,590 in reported general payments places this provider in the 75th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$54,705
Medicare patients
85
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron65$40,139
GemtesaVibegron43$31,009
Solifenacin Succinate42$2,180
Tamsulosin Hcl172$1,706
Methenamine Hippurate29$1,250
Oxybutynin Chloride ErOxybutynin Chloride44$750
Testosterone Cypionate17$739
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst27$713
Finasteride32$511
Tadalafil16$334
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim31$283
Alfuzosin Hcl ErAlfuzosin Hcl15$251
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip21$200
Levofloxacin47$173
Anastrozole14$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$552$40,13965 claims
Sumitomo Pharma America, Inc.Gemtesa$74$31,00943 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 878 urology providers in Texas.

Other urology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →